Axelopran + pembrolizumab for squamous cell carcinoma of head and neck

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 23 Jun 2026: Trial registered, NCT07662720

The trials

NCT07662720: A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer

State
Not started
Phase
Phase 1 and Phase 2
People
18 planned
Started
15 Jul 2026
Primary completion
31 Aug 2027
Arms
Axelopran in combination with Pembrolizumab in PDL-1 positive patients with HNSCC
Results
None posted
  1. 23 Jun 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.